Stocks · News reference

Telix Receives FDA's Fast Track Designation For Its BiPASS Program To Trace Prostate Cancer Prior To Biopsy

Sep 30, 2026, 1:38 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 6, 2026, 10:31 AMBenzinga Newsdesk
Telix Pharmaceuticals Says First Patients In US Dosed With Pixclara, FDA-Approved, Amino Acid Positron Emission Tomography Drug For Glioma Imaging
First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability.Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain
TLX
BenzingaSep 25, 2026, 2:29 PMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and maintains $20 price target.
TLX
BenzingaSep 23, 2026, 12:15 PMBenzinga Newsdesk
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target
Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperform and maintains $22 price target.
TLX